ketoconazole has been researched along with paclitaxel in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.89) | 18.2507 |
| 2000's | 20 (52.63) | 29.6817 |
| 2010's | 14 (36.84) | 24.3611 |
| 2020's | 1 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, ZS; Gupta, P; Lei, ZN; Li, YN; Li, ZH; Liu, HM; Liu, Y; Ma, LY; Wang, B; Wang, JQ; Zhang, XH; Zhao, B; Zhao, YD | 1 |
| Dubrovskyi, O; Dye, K; Gutgesell, LM; Huang, F; Li, Y; Ratia, K; Shen, Z; Thatcher, GRJ; Tonetti, DA; Xiong, R; Zhao, H; Zhao, J | 1 |
| Buarque De Gusmao, N; Guiraud, P; Seigle-Murandi, F; Steiman, R | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 2 |
| Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Choi, Y; Jin, Y; Jung, HY; Kaur, N; Kim, DK; Kim, EK; Kim, ES; Lee, K; Min, KH; Min, YK; Park, MK; Xia, Y | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Avery, VM; Sykes, ML | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Açık, L; Akbaş, H; Celik, ZB; Hökelek, T; Kılıç, Z; Koç, LY; Okumuş, A; Süzen, Y | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Collins, JM; Jamis-Dow, CA; Katki, AG; Klecker, RW | 1 |
| Blake, DS; Collins, JM; Jamis-Dow, CA; Klecker, RW; Pearl, ML; Watkins, PB | 1 |
| Blagosklonny, MV; Dixon, SC; Figg, WD | 1 |
| Agúndez, JA; García-Gamito, FJ; García-Martín, E; Martínez, C; Pizarro, RM | 1 |
| Cannon, MW; Jones, D; Kuebler, JP; Lee, SJ; Logothetis, CJ; Millikan, R; Thall, PF; Wade, J | 1 |
| Cederbaum, AI; Holownia, A | 1 |
| Aggarwal, A; Baranda, J; Reed, G; Van Veldhuizen, PJ; Williamson, S; Zulfiqar, M | 1 |
| Aubert, C; Bun, H; Bun, SS; Ciccolini, J; Fanciullino, R; Giacometti, S | 1 |
| Marks, B; Raucy, J; Trubetskoy, O; Yueh, MF; Zielinski, T | 1 |
| Acharya, MR; Desai, N; Figg, WD; Smith, NF; Sparreboom, A | 1 |
| Brown, MA; Logothetis, C; Millikan, RE; Pagliaro, LC; Thall, PF; Wen, S; Williams, D | 1 |
| Amato, RJ; Henary, H; Hernandez-McClain, J | 1 |
| Hiramatsu, Y; Masuyama, H; Nakamura, K; Nobumoto, E | 1 |
2 review(s) available for ketoconazole and paclitaxel
| Article | Year |
|---|---|
Approaches to protozoan drug discovery: phenotypic screening.
Topics: Drug Discovery; Humans; Molecular Structure; Neglected Diseases; Phenotype; Plasmodium falciparum; Protozoan Infections; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosoma cruzi | 2013 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for ketoconazole and paclitaxel
| Article | Year |
|---|---|
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Ketoconazole; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Treatment Outcome | 2003 |
Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Humans; Ketoconazole; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2003 |
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Topics: Aged; Algorithms; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Confidence Intervals; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Estramustine; Etoposide; Humans; Ketoconazole; Logistic Models; Male; Middle Aged; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Research Design; Survival Analysis; Treatment Outcome; Vinblastine; Vincristine | 2007 |
Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Doxorubicin; Estramustine; Humans; Ketoconazole; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Strontium Radioisotopes; Survival Rate; Treatment Outcome | 2008 |
32 other study(ies) available for ketoconazole and paclitaxel
| Article | Year |
|---|---|
Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance.
Topics: Administration, Oral; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Multiple; Gene Expression Regulation, Neoplastic; Humans; Intracellular Space; Models, Molecular; Molecular Docking Simulation; Protein Conformation; Protein Transport; Pyrimidines; Urea | 2018 |
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Fulvestrant; Humans; MCF-7 Cells; Mice; Models, Molecular; Piperazines; Protein Domains; Pyridines; Pyridones; Receptors, Estrogen; Tissue Distribution; Transcription Factors; Xenograft Model Antitumor Assays | 2020 |
Antimicrobial and antitumor activities of mycosporulone.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Bacteria; Cyclohexanes; Drug Screening Assays, Antitumor; Fungi; Humans; Microbial Sensitivity Tests; Spiro Compounds; Tumor Cells, Cultured | 1999 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors | 2001 |
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Binding Sites; Biological Transport, Active; Biomarkers; Cells, Cultured; Drug Interactions; Fluorescent Dyes; Humans | 2003 |
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives.
Topics: Adamantane; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cytochrome P-450 CYP3A; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Sarcoma; Structure-Activity Relationship | 2009 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Phosphorus-nitrogen compounds part 27. Syntheses, structural characterizations, antimicrobial and cytotoxic activities, and DNA interactions of new phosphazenes bearing secondary amino and pendant (4-fluorobenzyl)spiro groups.
Topics: Amines; Antifungal Agents; Antineoplastic Agents; Apoptosis; Candida; Cell Proliferation; Cell Survival; DNA; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HeLa Cells; Humans; MCF-7 Cells; Membrane Potential, Mitochondrial; Models, Molecular; Molecular Structure; Organophosphorus Compounds; Plasmids; Spiro Compounds; Structure-Activity Relationship | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences.
Topics: Animals; Biotransformation; Cimetidine; Cytochrome P-450 Enzyme System; Dexamethasone; Diphenhydramine; Drug Evaluation, Preclinical; Drug Interactions; Glycerol; Humans; In Vitro Techniques; Ketoconazole; Kinetics; Liver; Microsomes, Liver; Paclitaxel; Quinidine; Rats; Species Specificity; Surface-Active Agents; Taxoids; Tritium | 1995 |
Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole.
Topics: Antifungal Agents; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Erythromycin; Female; Humans; Ketoconazole; Ovarian Neoplasms; Oxidoreductases, N-Demethylating; Paclitaxel | 1997 |
Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Humans; Ketoconazole; Male; Microtubules; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Tumor Cells, Cultured; Vinblastine | 2000 |
Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Colon; Colorectal Neoplasms; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Ketoconazole; Male; Microsomes, Liver; Middle Aged; Mutation; Nifedipine; Oxidoreductases, N-Demethylating; Paclitaxel; Rectum | 2002 |
Threshold for antiproliferative and proapoptotic activity of ttaxol in HepG2 cells expressing human CYP3A4: effect of P-glycoprotein transporters.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Cytochromes c; Dose-Response Relationship, Drug; Hepatoblastoma; Humans; Ketoconazole; Necrosis; Paclitaxel; RNA, Messenger | 2003 |
Effect of several compounds on biliary excretion of paclitaxel and its metabolites in guinea-pigs.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Bile; Biotransformation; Dexamethasone; Dogs; Drug Interactions; Glucocorticoids; Guinea Pigs; Humans; Ketoconazole; Liver; Macaca fascicularis; Male; Mice; Microsomes, Liver; Models, Animal; Paclitaxel; Quercetin; Rabbits; Rats; Trimethoprim, Sulfamethoxazole Drug Combination | 2005 |
A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Chromans; Clotrimazole; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Dimethyl Sulfoxide; Enhancer Elements, Genetic; Enzyme Induction; Genes, Reporter; Genes, Synthetic; Humans; Ketoconazole; Liver Neoplasms; Lovastatin; Luciferases; Mifepristone; Neoplasm Proteins; Nifedipine; Omeprazole; Paclitaxel; Phenytoin; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Recombinant Fusion Proteins; Rifampin; Thiazolidinediones; Transcription, Genetic; Troglitazone; Troleandomycin | 2005 |
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Female; Hepatocytes; Humans; Ketoconazole; Liver; Liver-Specific Organic Anion Transporter 1; Mice; Mice, Inbred Strains; Oocytes; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Paclitaxel; Quinolines; Solute Carrier Organic Anion Transporter Family Member 1B3; Xenopus laevis | 2005 |
Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Female; Humans; Ketoconazole; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phthalic Acids; Pregnane X Receptor; Pregnenolone; Receptors, Steroid; RNA, Small Interfering; Signal Transduction | 2016 |